Discovery Labs is a specialty biotech company focused on creating life-saving products for patients with respiratory disease. Discovery Labs develops novel synthetic surfactant therapies with broad potential application across many respiratory diseases. The company’s fully synthetic surfactant technology has the potential to establish a new therapeutic approach to treat respiratory disease, with a targeted initial application in preterm infants. Discovery Labs’ lead surfactant product candidate is called SURFAXIN® for the prevention of respiratory distress syndrome (RDS) in premature infants. For more information visit the company’s Web site at www.discoverylabs.com
ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com
Let us hear your thoughts below: